Sabin Vaccine Institute
Named afterAlbert B. Sabin[1][2]
Established1993 (1993)[3][4][5]
Founders
TypeCharitable organization
Purposevaccination and disease prevention
HeadquartersWashington, D.C.
Coordinates38°54′01″N 77°02′46″W / 38.9002964°N 77.0460199°W / 38.9002964; -77.0460199
Amy Finan
Websitewww.sabin.org

Sabin Vaccine Institute (Sabin), located in Washington, D.C., is a nonprofit organization promoting global vaccine development, availability, and use. Through its work, Sabin hopes to reduce human suffering by preventing the spread of vaccine-preventable, communicable disease in humans through herd immunity and mitigating the poverty caused by these diseases.

Background

Founded in 1993[3][4][5] in honor of Albert B. Sabin, creator of the oral polio vaccine, Sabin works to reduce "human suffering from vaccine-preventable and neglected tropical diseases (NTDs)."[1][2] The organization endeavors to reach its goal via its three main programs: Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases, and Vaccine Advocacy and Education.[6] Through its Product Development Partnership (PDP), Sabin has worked with organizations such as King Saud University,[7] Texas Children's Hospital Center,[8] International Vaccine Institute,[9] and George Washington University School of Medicine & Health Sciences[10] toward its goals, with funding and support from the Bill & Melinda Gates Foundation,[10][11] the National Institute of Allergy and Infectious Diseases,[12] the Dutch Ministry of Foreign Affairs,[13] the Brazilian Ministry of Health[13] and other benefactors.

Vaccine development and research

In 2012, Sabin partnered with International Vaccine Institute to combine their research, development, and promotion efforts in Asia, Africa, and the Americas.[9] Sabin is currently working on multiple vaccines for humans[1] including vaccines for Hookworm infection (Na-GST-1, Na-APR-1),[10][13][14][15] Schistosomiasis (Sm-TSP-2),[16][17][18][19] Chagas disease (Tc24, TSA-1),[8][20][21] Leishmaniasis (Ld-NH36, PdSP15),[22][23][24] severe acute respiratory syndrome (SARS)/Middle East respiratory syndrome (MERS) (Pan-β-CoVax),[25][26][27] Soil-transmitted helminthiasis (STH),[28][29] and Onchocerciasis (Ov-103, Ov-RAL-2).[30][31][32][33]

Neglected tropical diseases

In 2006, Sabin co-founded the Global Network for Neglected Tropical Diseases in order "to raise the awareness, political will and funding necessary to control and eliminate the most common NTDs."[34] Through its work on NTDs, Sabin hopes to reduce poverty caused by these diseases as many of them have been shown to adversely affect "childhood cognitive development among the poor, thereby reinforcing poverty."[35]

Advocacy and education

Sabin works with experts and organizations from around the world to advance knowledge of both infectious diseases and the vaccines that can prevent them. Through the International Association of Immunization Managers (IAIM) Network, Sabin arranges international forums to improve the success rates of immunization programs.[6] Sabin serves as the secretariat for the Coalition against Typhoid, and its mission is to raise awareness of typhoid and salmonellosis.[36]

Two months prior to the COVID-19 pandemic, Bruce Gellin, President of the Sabin Vaccine Institute, was member to a meeting titled "Universal Flu Vaccine" (dated October 29, 2019) with other government officials including Anthony Fauci, speaking about the need to "blow up the system" in-order to bypass regulatory control on mRNA vaccines. Also discussed in the meeting, held at the Milken Institute School of Public Health, was the need to create an "aura of excitement" and "make influenza sexy" in order to receive government funding and have hyper-production of the mRNA vaccines which he and others in the meeting believed were superior to "traditional egg-based vaccines".[37]

Board of directors

  • Axel Hoos (chairman)
  • Amy Finan (ex officio trustee)
  • Peter L. Thoren (vice chairman)
  • Wendy Commins Holman
  • Kenneth Kelley
  • Paul Maddon
  • Michael W. Marine
  • Regina Rabinovich
  • Philip K. Russell (past chairman)

Gold medal award

First awarded in 1994, the Albert B. Sabin Gold Medal is presented by Sabin each year to one or more persons who have made a major contribution to the field of vaccinology or related fields. The award is given in honor of the work of Albert B. Sabin.[38] Past recipients of the award include Samuel L. Katz (2003), Joseph L. Melnick (1996), and Ruth S. Nussenzweig (2008).[39]

References

  1. 1 2 3 "SABIN Vaccine Institute". Michelson Medical Research Foundation. Retrieved 2 September 2017.
  2. 1 2 Miller, Dr Yvette Alt (2020-03-17). "Eradicating Polio: When Two Jewish Researchers Changed the World". aishcom. Retrieved 2020-05-20.
  3. 1 2 "In Memoriam: Heloisa Sabin". Sabin. 17 October 2016. Archived from the original on 12 May 2021. Retrieved 6 September 2017.
  4. 1 2 "The Legacy of Albert B. Sabin". Sabin. October 2012. Retrieved 6 September 2017.
  5. 1 2 "Sabin Institute To Develop GSK's Ebola and Marburg Virus Vaccines". www.precisionvaccinations.com. Retrieved 2020-05-20.
  6. 1 2 "Immunization Manager Network". Sabin. 28 April 2017. Archived from the original on 4 December 2020. Retrieved 2 September 2017.
  7. ↑ "Sabin PDP, King Saud University Sign Project Agreement to Build Vaccine Research and Development Capacity in Saudi Arabia". U.S. Embassy & Consulates in Saudi Arabia. 16 November 2015. Archived from the original on 9 September 2017. Retrieved 9 September 2017.
  8. 1 2 "Texas Children's Hospital Center for Vaccine Development awarded grant to develop therapeutic vaccine for chagas disease". Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation. 17 July 2015. Archived from the original on 28 July 2016. Retrieved 8 September 2017.
  9. 1 2 "IVI and Sabin Vaccine Institute Form a Strategic Alliance to Develop Vaccines for the World's Poor". International Vaccine Institute. 18 July 2012. Archived from the original on 6 September 2017. Retrieved 6 September 2017.
  10. 1 2 3 "Hookworm Vaccine Research". Bill & Melinda Gates Foundation. Archived from the original on 11 September 2015. Retrieved 8 September 2017.
  11. ↑ "Sabin Vaccine Colloquium". Bill & Melinda Gates Foundation. Archived from the original on 20 September 2015. Retrieved 20 September 2017.
  12. ↑ Dipali Pathak (30 August 2016). "Grant to develop chikungunya virus vaccine awarded". Baylor College of Medicine. Archived from the original on 20 May 2017. Retrieved 3 October 2017.
  13. 1 2 3 Hotez, Peter J.; Diemert, David; Bacon, Kristina M.; Beaumier, Coreen; Bethony, Jeffrey M.; Bottazzi, Maria Elena; Brooker, Simon; Couto, Artur Roberto; da Silva Freire, Marcos; Homma, Akira; Lee, Bruce Y.; Loukas, Alex; Loblack, Marva; Morel, Carlos Medicis; Oliveira, Rodrigo Correa; Russell, Philip K. (18 April 2013). "The Human Hookworm Vaccine". Vaccine. 31 (Suppl 2): B227–B232. doi:10.1016/j.vaccine.2012.11.034. ISSN 0264-410X. PMC 3988917. PMID 23598487.
  14. ↑ "Status of Vaccine Research and Development of Vaccines for Human Hookworm Infection" (PDF). World Health Organization. Archived from the original (PDF) on 30 August 2017. Retrieved 8 September 2017.
  15. ↑ "Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children - Full Text View". clinicaltrials.gov. Archived from the original on 18 September 2017. Retrieved 18 September 2017.
  16. ↑ Tebeje, Biniam Mathewos; Harvie, Marina; You, Hong; Loukas, Alex; McManus, Donald P. (30 September 2016). "Schistosomiasis vaccines: where do we stand?". Parasites & Vectors. 9 (1): 528. doi:10.1186/s13071-016-1799-4. ISSN 1756-3305. PMC 5045607. PMID 27716365.
  17. ↑ Merrifield, Maureen; Hotez, Peter J.; Beaumier, Coreen M.; Gillespie, Portia; Strych, Ulrich; Hayward, Tara; Bottazzi, Maria Elena (3 June 2016). "Advancing a vaccine to prevent human schistosomiasis". Vaccine. 34 (26): 2988–2991. doi:10.1016/j.vaccine.2016.03.079. ISSN 1873-2518. PMID 27036511.
  18. ↑ "A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults - Full Text View". ClinicalTrials.gov. 22 June 2017. Archived from the original on 18 September 2017. Retrieved 18 September 2017.
  19. ↑ "A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults - Full Text View". ClinicalTrials.gov. Archived from the original on 18 September 2017. Retrieved 18 September 2017.
  20. ↑ Beaumier, Coreen M.; Gillespie, Portia M.; Strych, Ulrich; Hayward, Tara; Hotez, Peter J.; Bottazzi, Maria Elena (3 June 2016). "Status of vaccine research and development of vaccines for Chagas disease". Vaccine. 34 (26): 2996–3000. doi:10.1016/j.vaccine.2016.03.074. ISSN 1873-2518. PMID 27026146.
  21. ↑ "Chagas". Sabin. 28 April 2017. Archived from the original on 12 July 2017. Retrieved 18 September 2017.
  22. ↑ Gillespie, Portia M.; Beaumier, Coreen M.; Strych, Ulrich; Hayward, Tara; Hotez, Peter J.; Bottazzi, Maria Elena (3 June 2016). "Status of vaccine research and development of vaccines for leishmaniasis". Vaccine. 34 (26): 2992–2995. doi:10.1016/j.vaccine.2015.12.071. ISSN 1873-2518. PMID 26973063.
  23. ↑ Asojo, Oluwatoyin A.; Kelleher, Alan; Liu, Zhuyun; Pollet, Jeroen; Hudspeth, Elissa M.; Rezende, Wanderson C.; Groen, Mallory Jo; Seid, Christopher A.; Abdeladhim, Maha; Townsend, Shannon; Castro, Waldione de; Mendes-Sousa, Antonio; Bartholomeu, Daniella Castanheira; Fujiwara, Ricardo Toshio; Bottazzi, Maria Elena; Hotez, Peter J.; Zhan, Bin; Oliveira, Fabiano; Kamhawi, Shaden; Valenzuela, Jesus G. (9 March 2017). "Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis". PLOS Neglected Tropical Diseases. 11 (3): e0005374. doi:10.1371/journal.pntd.0005374. ISSN 1935-2735. PMC 5344329. PMID 28278244.
  24. ↑ "Leishmaniasis". Sabin. 28 April 2017. Archived from the original on 12 July 2017. Retrieved 18 September 2017.
  25. ↑ Jiang, Shibo; Bottazzi, Maria Elena; Du, Lanying; Lustigman, Sara; Tseng, Chien-Te Kent; Curti, Elena; Jones, Kathryn; Zhan, Bin; Hotez, Peter J (December 2012). "Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome". Expert Review of Vaccines. 11 (12): 1405–1413. doi:10.1586/erv.12.126. ISSN 1476-0584. PMC 3586247. PMID 23252385.
  26. ↑ Chen, Wen-Hsiang; Du, Lanying; Chag, Shivali M.; Ma, Cuiqing; Tricoche, Nancy; Tao, Xinrong; Seid, Christopher A.; Hudspeth, Elissa M.; Lustigman, Sara; Tseng, Chien-Te K.; Bottazzi, Maria Elena; Hotez, Peter J.; Zhan, Bin; Jiang, Shibo (2014). "Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate". Human Vaccines & Immunotherapeutics. 10 (3): 648–658. doi:10.4161/hv.27464. ISSN 2164-554X. PMC 4130269. PMID 24355931.
  27. ↑ "SARS/MERS". Sabin. 28 April 2017. Archived from the original on 12 July 2017. Retrieved 18 September 2017.
  28. ↑ Zhan, Bin; Beaumier, Coreen M; Briggs, Neima; Jones, Kathryn M; Keegan, Brian P; Bottazzi, Maria Elena; Hotez, Peter J (2014). "Advancing a multivalent 'Pan-anthelmintic' vaccine against soil-transmitted nematode infections". Expert Review of Vaccines. 13 (3): 321–331. doi:10.1586/14760584.2014.872035. ISSN 1476-0584. PMC 3934375. PMID 24392641.
  29. ↑ "Helminth Vaccine Discovery Program funded by Dr. Gary K. Michelson". Michelson Medical Research Foundation. 27 April 2014. Retrieved 8 September 2017.
  30. ↑ "Onchocerciasis". Sabin. 28 April 2017. Archived from the original on 12 July 2017. Retrieved 11 September 2017.
  31. ↑ Hotez, Peter J.; Bottazzi, Maria Elena; Zhan, Bin; Makepeace, Benjamin L.; Klei, Thomas R.; Abraham, David; Taylor, David W.; Lustigman, Sara (29 January 2015). "The Onchocerciasis Vaccine for Africa—TOVA—Initiative". PLOS Neglected Tropical Diseases. 9 (1): e0003422. doi:10.1371/journal.pntd.0003422. ISSN 1935-2735. PMC 4310604. PMID 25634641.
  32. ↑ "The Partners". The Onchocerciasis Vaccine for Africa Initiative. Archived from the original on 14 February 2017. Retrieved 11 September 2017.
  33. ↑ "The Onchocerciasis Vaccine for Africa (TOVA) - A global initiative to advance river blindness vaccine". Edinburgh Infectious Diseases. 27 August 2015. Archived from the original on 11 September 2017. Retrieved 11 September 2017.
  34. ↑ "The Global Network for Neglected Tropical Diseases". Sabin. 11 August 2017. Archived from the original on 6 September 2017. Retrieved 9 September 2017.
  35. ↑ Hotez, Peter J (16 December 2014). "The Medical Biochemistry of Poverty and Neglect". Molecular Medicine. 20 (Suppl 1): S31–S36. doi:10.2119/molmed.2014.00169. ISSN 1076-1551. PMC 4374519. PMID 25549231.
  36. ↑ "Coalition Against Typhoid". Coalition Against Typhoid. Archived from the original on 14 September 2017. Retrieved 14 September 2017.
  37. ↑ "Universal Flu Vaccine". C-SPAN.org. 2019-10-29. Retrieved 2021-10-10.
  38. ↑ "The Albert B. Sabin Gold Medal Award". Sabin. 12 September 2012. Archived from the original on 28 August 2017. Retrieved 21 September 2017.
  39. ↑ "The Albert B. Sabin Gold Medal Award". Sabin. 12 September 2012. Archived from the original on 28 August 2017. Retrieved 4 October 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.